A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Surmodics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 1,400 shares of SRDX stock, worth $55,412. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,400
Previous 500 180.0%
Holding current value
$55,412
Previous $21,000 157.14%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$38.47 - $42.24 $472,988 - $519,340
-12,295 Reduced 81.84%
2,728 $105,000
Q2 2024

Aug 14, 2024

SELL
$25.39 - $42.1 $952,810 - $1.58 Million
-37,527 Reduced 71.41%
15,023 $631,000
Q1 2024

May 15, 2024

BUY
$27.44 - $35.56 $739,288 - $958,057
26,942 Added 105.21%
52,550 $1.54 Million
Q4 2023

Feb 14, 2024

SELL
$28.47 - $38.49 $1.39 Million - $1.88 Million
-48,782 Reduced 65.58%
25,608 $930,000
Q3 2023

Nov 14, 2023

SELL
$28.28 - $38.36 $1.72 Million - $2.34 Million
-60,937 Reduced 45.03%
74,390 $2.39 Million
Q2 2023

Aug 14, 2023

BUY
$17.67 - $31.31 $460,692 - $816,314
26,072 Added 23.86%
135,327 $4.24 Million
Q1 2023

May 15, 2023

BUY
$17.13 - $38.52 $1.77 Million - $3.97 Million
103,184 Added 1699.62%
109,255 $2.49 Million
Q4 2022

Feb 14, 2023

SELL
$29.44 - $37.31 $104,747 - $132,748
-3,558 Reduced 36.95%
6,071 $207,000
Q3 2022

Nov 14, 2022

SELL
$28.84 - $38.92 $8,709 - $11,753
-302 Reduced 3.04%
9,629 $293,000
Q2 2022

Aug 15, 2022

BUY
$33.25 - $45.11 $19,318 - $26,208
581 Added 6.21%
9,931 $369,000
Q3 2021

Nov 15, 2021

SELL
$52.8 - $60.32 $641,836 - $733,249
-12,156 Reduced 56.52%
9,350 $520,000
Q2 2021

Aug 16, 2021

SELL
$51.29 - $59.15 $253,270 - $292,082
-4,938 Reduced 18.67%
21,506 $1.17 Million
Q1 2021

May 17, 2021

SELL
$42.18 - $56.07 $465,540 - $618,844
-11,037 Reduced 29.45%
26,444 $1.48 Million
Q4 2020

Feb 16, 2021

BUY
$35.18 - $43.52 $174,774 - $216,207
4,968 Added 15.28%
37,481 $1.63 Million
Q3 2020

Nov 16, 2020

BUY
$37.98 - $48.72 $775,703 - $995,057
20,424 Added 168.95%
32,513 $1.27 Million
Q2 2020

Aug 14, 2020

SELL
$31.07 - $44.74 $52,384 - $75,431
-1,686 Reduced 12.24%
12,089 $523,000
Q1 2020

May 15, 2020

SELL
$22.46 - $42.24 $547,350 - $1.03 Million
-24,370 Reduced 63.89%
13,775 $459,000
Q4 2019

Feb 14, 2020

SELL
$39.01 - $47.51 $652,442 - $794,604
-16,725 Reduced 30.48%
38,145 $1.58 Million
Q3 2019

Nov 14, 2019

BUY
$38.66 - $47.41 $925,636 - $1.14 Million
23,943 Added 77.42%
54,870 $2.51 Million
Q2 2019

Aug 14, 2019

SELL
$38.23 - $47.43 $1.96 Million - $2.44 Million
-51,348 Reduced 62.41%
30,927 $1.34 Million
Q1 2019

May 15, 2019

BUY
$41.26 - $58.35 $1.29 Million - $1.82 Million
31,167 Added 60.98%
82,275 $0
Q4 2018

Feb 14, 2019

BUY
$44.93 - $73.38 $1.2 Million - $1.97 Million
26,813 Added 110.36%
51,108 $2.42 Million
Q3 2018

Nov 13, 2018

BUY
$56.85 - $80.35 $517,789 - $731,827
9,108 Added 59.97%
24,295 $0
Q2 2018

Aug 10, 2018

BUY
$35.85 - $57.05 $544,453 - $866,418
15,187 New
15,187 $0
Q1 2018

May 11, 2018

SELL
$27.0 - $38.5 $392,256 - $559,328
-14,528 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$28.0 - $33.2 $62,916 - $74,600
2,247 Added 18.3%
14,528 $407,000
Q3 2017

Nov 09, 2017

BUY
$24.5 - $31.1 $300,884 - $381,939
12,281
12,281 $381,000

Others Institutions Holding SRDX

About SURMODICS INC


  • Ticker SRDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 14,005,000
  • Market Cap $554M
  • Description
  • Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device s...
More about SRDX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.